Hello and Welcome! Thanks for your interest in knowing more about us. We have been in the US Equity Market since year 2001. Over the years, we have developed expertise in specific indices, assets and ETFs, and they form our high conviction set today. We get many opportunities from within this set every year. We are short term traders and long term investors.
We been helping Clients/Investors since 2008 in various ways, including: S&P500 and Nasdaq100 futures and ETFs, Nifty and Bank Nifty trading, Bitcoin and Crypto investing, and Crude Oil futures trading. For all long term investments, we use ETFs related to Software and Biotech industry.
Our top equity investment since year 2010 has been the Nasdaq ETF (QQQ) and we have been suggesting the same to all alumni and investors in our network. It has grown from $50 in year 2010 to $300 in year 2020. This ETF has a bright future, because we are in the “Tech Century” and only 20 years have passed so far, and 80 years are ahead!
We have over 250 Private Investors and Family Offices in our network, and our goal is to provide them valuable analysis and direction that will enable short term trading gains, and long term investment gains.
JMD Capital team includes professionals with diverse experience in financial markets, including Equity investing, Commodity trading, Market research, CPA and Tax Consultants. Our team members are based worldwide, but our focus is the US market.
Shankar AVSB
Founder & Director
https://twitter.com/shankx
https://www.linkedin.com/in/avsbs/
Shankar is the Founder-Director of JMD Capital. He started the company with the goal to help Investors worldwide to participate and benefit from the “Tech Century” that we are in. His operational focus is on S&P500 and Nasdaq futures trading, and creating trading and investing gains for Clients/Investors using public listed Stocks and ETFs. Shankar has 20 years of experience in the Tech industry in various roles, as an Executive in the Software industry, based in Boston, MA and Palo Alto, CA and London, UK, and as an Investor in Software and Biotech industries. After completing graduation in Electrical Engineering and MBA, Shankar studied Molecular Biology at Stanford University in year 2001-2002 to understand the implications of Genetic Engineering and Genomics on the Biotech industry. Shankar has been a biotech investor since year 2001 with initial investments in Amgen and Biogen. He has been trading Biotech Industry ETFs, which helps investors earn superior returns.
“Over the last 12 years, we have seen a wide range Private Investors and Family Offices, and it always helps to have a simple investment strategy, because a simple strategy can remain agile and handle volatile and uncertain market conditions. We don’t need many different funds, ETFs or stocks for creating good gains — in fact we need very few ETFs to create good gains year after year.
The market is full of noise and distraction, but we must focus on a few reliable ETFs to achieve our goals. Our core long term investment is the Nasdaq ETF (QQQ). This is the foundation for next 50 years of investments. For yearly trading gains, once we see a clear upside, we can increase our position with leveraged ETFs.
So the summary of our work is to find Indices/ETFs/Stocks/Commodities with reliable near term upside and once we have found it, the gains are a natural consequence. Ideally, we need 4-5 such investment ideas in parallel to distribute the capital and risk nicely.”
We trade S&P500 and Nasdaq futures/ETFs, and focused equity investing in Software and Biotech stocks/ETFs. We have a strong preference for ETFs because of the simplicity and stability they offer for long term investments.
For example, our core Biotech portfolio has delivered 20% CAGR over last 10 years, and our Biotech trading has given another 20% above that, thereby creating a very good result for long term investments. We have to understand that billions of dollars are waiting on the sidelines to support all new R&D efforts in Biotech, and latest software innovations are accelerating the R&D efforts. We can’t get involved in every Biotech venture, but we can stay invested at the Biotech industry level, and use a few public listed stocks and ETFs, to create attractive gains over next 10-20 years. We can safely say that all Investors can aim to earn 25-30% CAGR over next 10-20 years on their Biotech portfolio allocation with our direction and guidance.
Investors worldwide can benefit from our market analysis and trading experience, through our Annual Fixed Fee service, or 80-20 profit sharing model. Investment Advisors can subscribe to our market research to deliver superior gains to their clients. Please contact us to learn more. Thanks.